Related Experiment Videos
The effect of thio-TEPA on developing and established mammalian bladder tumors
Abstract:
The inhibitory effect of thio-TEPA on both developing and established mammalian bladder cancer was tested in the FANFT model system using female C3H/He mice. This model allows the histologic evaluation of the entire target organ, a major advantage over clinical trials, which have relied largely on endoscopic appearance for determination of response. A powerful carcinogen, FANFT is known to cause bladder carcinoma in at least 90% of these animals within 12 months. The tumors develop through a spectrum of morphologic changes including hyperplasia, dysplasia, and carcinoma in situ. Animals were divided into equally sized control and test groups and either thio-TEPA or saline was administered on a schedule designed to correspond to that used in clinical trials. Bladders from 159 mice were evaluated grossly, microscopically and in some instances, ultrastructurally, for the presence of tumor or other intraepithelial lesions. When compared to controls, thio-TEPA had no statistically significant inhibitory effect on either developing or established bladder tumors. The drug did, however, cause a statistically significant decrease in the frequency of high-grade, high-stage lesions when given during tumor development and may retard the evolution of such neoplasms from low-grade noninvasive carcinomas. The correlation of these experimental findings with the reportedly beneficial results of clinical trials is discussed.
Insights
Thio-TEPA did not significantly inhibit developing or established mammalian bladder cancer in the FANFT mouse model. However, it reduced high-grade lesions during tumor development, potentially slowing cancer progression.
Area of Science:
- Oncology
- Pharmacology
- Experimental Pathology
Background:
- Mammalian bladder cancer research often relies on clinical trial data, which can be limited by subjective response assessments.
- The FANFT-induced bladder cancer model in C3H/He mice offers a comprehensive system for histologic evaluation of the entire target organ.
- FANFT is a potent carcinogen inducing bladder carcinoma in over 90% of mice within 12 months, progressing through hyperplasia, dysplasia, and carcinoma in situ.
Purpose of the Study:
- To evaluate the inhibitory effect of thio-TEPA on both developing and established bladder cancer in a mammalian model.
- To assess thio-TEPA's impact on tumor progression and lesion grade within the FANFT-induced bladder cancer model.
- To correlate experimental findings with existing clinical trial data on thio-TEPA efficacy.
Main Methods:
- Female C3H/He mice were utilized in the FANFT model system to induce bladder cancer.
- Animals were divided into control (saline) and test (thio-TEPA) groups, receiving treatment on a schedule mimicking clinical trials.
- A total of 159 mouse bladders were examined grossly, microscopically, and ultrastructurally for tumors and intraepithelial lesions.
Main Results:
- Thio-TEPA demonstrated no statistically significant inhibitory effect on the development or establishment of bladder tumors compared to controls.
- A significant decrease in the frequency of high-grade, high-stage lesions was observed when thio-TEPA was administered during tumor development.
- The drug may potentially retard the progression of low-grade, noninvasive carcinomas to more advanced neoplasms.
Conclusions:
- Thio-TEPA lacks significant efficacy in inhibiting overall bladder tumor burden in the FANFT mouse model.
- The chemotherapeutic agent may play a role in mitigating the progression of bladder cancer to higher-grade, more invasive stages.
- Further investigation is warranted to understand thio-TEPA's nuanced effects on bladder cancer evolution and its clinical relevance.